Corporate Profile

Quince is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. 

Our lead asset, EryDex, which is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T), is expected to begin a pivotal Phase 3 clinical trial in the second quarter of 2024. Currently, there are no approved treatments for A-T and the market represents a $1+ billion estimated peak sales opportunity globally. EryDex utilizes a highly differentiated technology platform for autologous intracellular drug encapsulation (AIDE). Our proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once monthly treatment period. It is also designed to allow for the chronic administration of the therapeutic.

Quince’s  flexible and expandable AIDE technology platform is designed to  deliver a variety of therapeutics, ranging from small to large molecules, as well as biologics. We intend to investigate additional potential applications of the AIDE technology platform as it provides Quince with opportunities for future indication expansion.

Investor Relations

News Releases

06 May '24
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 6, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Reports